Travere Therapeutics, Inc. Appoints Ruth Williams-Brinkley to its Board of Directors
September 14, 2021 at 04:30 pm EDT
Share
Travere Therapeutics, Inc. announced the appointment of Ruth Williams-Brinkley to the company’s board of directors, effective immediately. Williams-Brinkley brings to the company more than 35 years of executive leadership in care delivery and health plan operations. Williams-Brinkley has served as President of the Kaiser Foundation Health Plan for the Mid-Atlantic States since 2020. She joined Kaiser Permanente in 2017 as President of Kaiser Foundation Health Plan and Hospitals of the Northwest, in Portland, Oregon. Prior to her roles at Kaiser Permanente, Williams-Brinkley served as CEO of KentuckyOne Health. Before joining KentuckyOne Health, Williams-Brinkley served as president and CEO of Carondelet Health Network in Tucson, Arizona, and as president and CEO of Memorial Healthcare System in Chattanooga, Tennessee. Williams-Brinkley serves on the not-for-profit boards of DePaul University in Chicago, Illinois and the Clinical Center Research Hospital Board of the National Institutes of Health (NIH) in Washington, D.C., as well as on the board of directors of University of Phoenix.
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Companyâs Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).